Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence DOI Creative Commons
Anqi Lin,

Yanxi Ding,

Zhengrui Li

et al.

Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)

Published: March 27, 2025

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a primary first-line treatment for type 2 diabetes. This has raised concerns about their impact on cancer risk, spurring extensive research. review systematically examines the varied effects of GLP-1RAs risk different types tumors, including overall and specific cancers such thyroid, pancreatic, reproductive system, liver, colorectal cancers. The potential biological mechanisms underlying influence are complex, involving metabolic regulation, direct antitumor effects, immune modulation, epigenetic changes. A systematic comparison with other antidiabetic agents reveals notable differences in across drug classes. Additionally, critical factors that shape relationship between thoroughly analyzed, patient demographics, comorbidities, regimens, lifestyle factors, offering essential insights developing individualized protocols. Despite significant research progress, gaps remain. Future should prioritize elucidating molecular behind refining strategies, investigating early tumor prevention applications, assessing benefits non-diabetic populations, advancing development novel therapies, establishing robust safety monitoring frameworks, building precision medicine decision-making platforms. These efforts aim to establish roles prevention. treatment, thereby progress medicine.

Language: Английский

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence DOI Creative Commons
Anqi Lin,

Yanxi Ding,

Zhengrui Li

et al.

Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)

Published: March 27, 2025

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a primary first-line treatment for type 2 diabetes. This has raised concerns about their impact on cancer risk, spurring extensive research. review systematically examines the varied effects of GLP-1RAs risk different types tumors, including overall and specific cancers such thyroid, pancreatic, reproductive system, liver, colorectal cancers. The potential biological mechanisms underlying influence are complex, involving metabolic regulation, direct antitumor effects, immune modulation, epigenetic changes. A systematic comparison with other antidiabetic agents reveals notable differences in across drug classes. Additionally, critical factors that shape relationship between thoroughly analyzed, patient demographics, comorbidities, regimens, lifestyle factors, offering essential insights developing individualized protocols. Despite significant research progress, gaps remain. Future should prioritize elucidating molecular behind refining strategies, investigating early tumor prevention applications, assessing benefits non-diabetic populations, advancing development novel therapies, establishing robust safety monitoring frameworks, building precision medicine decision-making platforms. These efforts aim to establish roles prevention. treatment, thereby progress medicine.

Language: Английский

Citations

0